Background: With the introduction of sofosbuvir-based regimens, high cure rates and
decreased duration has been achieved. Several studies showed variances in SVR rates between different
genotypes, with lower rates of SVR among cirrhotic patients. The aim of our study was to assess
the safety and effectiveness of sofosbuvir-based antiviral regimens for the treatment of HCVinfected
Egyptian cirrhotic patients.
Methods: This was a retrospective, observational, and comparative study. A total of nine hundred
and forty-six cirrhotic patients with chronic HCV genotype 4 infection, who were eligible for direct
acting drugs (DAAs) therapy, were enrolled. The primary outcome measures were the number
of patients with successful eradication of the virus evidenced by SVR at 12 weeks after discontinuation
of therapy (SVR12), and the secondary outcome measures were the incidence of adverse effects
associated with the tested HCV therapy.
Results: Among the 946 patients enrolled in the study, 527 patients (55.7%) were males and 419
patients (44.3%) were females with a mean age of 54.00±8.88 years. 20.2% were diabetics and
19.1% were hypertensive. Patients were classified according to Child-Pugh classifications; 818 patients
(86.46%) were Child-Pugh class A cirrhosis, while 28 patients (13.53%) were Child-Pugh
class B cirrhosis. The SVR12 rate was 96.93% (917 /946). Treatment response in the Child-Pugh
class A cirrhosis was 794 (97%) after 12 weeks, while treatment response in the Child-Pugh class
B cirrhosis was 123 (96%). Mild side effects were observed in 76 patients.
Conclusions: Sofosbuvir based regimens were effective and safe in the treatment of cirrhotic patients
with chronic hepatitis C genotype 4.